Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
+ 17 more
Nothing from your lists
AtaiBeckley Inc. · “On September 11, 2026 (the “ Closing Date ”), pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the “ Merger ”), with the Company surviving as a wholly owned subsidiary of Parent.”¶1
New Fortress Energy Inc. · “The Company has now completed all steps, satisfied all conditions and obtained all necessary approvals in relation to the implementation of the UK RP and the Restructuring Effective Date occurred today.”¶1
Skye Bioscience, Inc. · “On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date.”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
The Merger closed on September 8, 2026, Second Merger Sub became Korsana Biosciences Operating Company, LLC, and Cyclerion changed its name to Korsana Biosciences, Inc.¶1¶2¶3
Immediately before the First Merger, investors purchased securities for gross proceeds of approximately $380.0 million, and Korsana securityholders owned approximately 98.83% of the Company post-Merger.¶4¶5
The Exchange Ratio was 0.2074 shares of Cyclerion common stock for each share of Korsana common stock, and the Company common stock began trading under KRSA after a 1-for-7 reverse stock split.¶6¶7¶8
Korsana generated net losses of $17.4 million and $30.9 million for the three and six months ended June 30, 2026.
On September 11, 2026, the Company consummated its restructuring, separated into BrazilCo and CoreCo, and terminated specified debt instruments and related obligations while releasing associated liens.¶2¶3¶4
Plan Creditors received 100% of BrazilCo, $571.3 million in New CoreCo Take-Back Term Loans, 2,454,936 preferred shares, and 10,608,922 Class A common shares representing 65% of CoreCo common stock.¶5¶6¶7¶8¶9
The Company raised $136.5 million of new financing, amended its letter of credit facility to provide a $250 million commitment, and BrazilCo paid approximately $74 million to CoreCo.¶10¶11¶12
The Company effected a 1-for-50 reverse stock split, removed the staggered board structure, and replaced plurality voting with majority voting for directors.
Volato closed its merger with Alignment Engine Inc. on September 11, 2026, with Volato Alignment Merger Sub, LLC surviving as a wholly-owned subsidiary of Volato.¶1
Aligned securityholders received 79,078 shares of Series A Preferred Stock and 316,312 shares of Series A-1 Preferred Stock, convertible with options and warrants into 95% of Volato Common Stock.¶2
Volato issued a senior unsecured convertible promissory note with an aggregate original principal amount of $7,500,000, maturing September 11, 2027.¶3
At Closing, Matthew Liotta resigned as Chief Executive Officer, and the Board appointed Christopher Ensey as Chief Executive Officer and a member of the Board.
On September 10, 2026, the Company and its subsidiary guarantors entered into a Forbearance Agreement with lenders, noteholders, and royalty financing investors.¶1
The Company did not pay the approximately $15.8 million principal installment due September 10, 2026, and the nonpayment constituted an Event of Default.¶2¶3
The Company agreed to pay $20.0 million in fees and will issue 20,000 shares of Convertible Preferred Stock at $1,000 per share, with issuance expected on September 17, 2026.¶4¶5
The Company stated that existing liquidity would fund current operating plans until October 15, 2026, and absent additional funding or strategic transactions it would be unable to continue as a going concern beyond that date.¶6
On September 11, 2026, Merger Sub merged with and into AtaiBeckley, and each eligible common share converted into $6.75 in cash plus one contingent value right.¶1¶2¶3
Each contingent value right represents up to an aggregate of $2.50 in cash per right upon specified clinical and regulatory milestones.¶2¶4
AtaiBeckley notified Nasdaq of the merger, requested suspension of common-stock trading, and requested a Form 25 to delist and deregister the common stock.¶5¶6
AtaiBeckley became a wholly owned subsidiary of Eli Lilly, its directors and executive officers resigned, new directors and officers were appointed, and its certificate and bylaws were amended and restated.¶7¶8¶9¶10
On September 11, 2026, Oklo entered into an equity distribution agreement allowing it to offer and sell Class A common stock with aggregate gross sales proceeds of up to $1,000,000,000.¶1¶2
The termination of the Prior Sales Agreement was effective as of the close of business on September 10, 2026, without termination penalties.¶3¶4
Oklo sold 17,971,448 shares of Common Stock for gross proceeds of approximately $1,000,000,000 under the Prior Sales Agreement and will make no further sales under it.¶5
Nautilus Biotechnology entered into an at-the-market Sales Agreement with TD Securities (USA), LLC to sell up to $125,000,000 of common stock, with TD Cowen entitled to up to 3.0% of gross proceeds as compensation.¶1¶2
Nautilus Biotechnology and TD Cowen mutually terminated the February 28, 2024 Prior Sales Agreement, under which none of the Company’s Common Stock was sold.¶3
Skye Bioscience provided notice terminating its Master Services Agreement with Lohman & Associates, Inc., effective September 8, 2026, following John P. Sharp’s resignation.¶2¶1
John P. Sharp resigned as Chief Financial Officer on September 8, 2026, and Punit Dhillon was appointed principal financial and accounting officer effective that date, with his other roles and compensation unchanged.¶1¶3¶4
The company said Mr. Sharp’s departure did not result from any disagreement concerning financial statements, internal controls, operations, policies or practices.¶5
Skye regained compliance with Nasdaq’s minimum bid price requirement after its common stock had a closing bid price at or greater than $1.00 per share for the last 10 consecutive business days from August 24 through September 4, 2026.¶6
On September 10, 2026, Q/C Technologies, Inc. and Chelsea Voss mutually terminated their consulting agreement, effective immediately.¶2
On September 10, 2026, the Company and Ocean Avenue Holdings LLC mutually terminated their consulting agreement, effective immediately.¶3
On September 10, 2026, Chelsea Voss resigned from the Company’s Board of Directors, without disagreement with its operations, policies or practices.¶1
Gossamer Bio filed a Delaware Certificate of Amendment effecting a 1-for-80 reverse stock split and a proportionate reduction in authorized shares, effective at 11:59 p.m. Eastern Time on September 10, 2026.¶2¶1
Every 80 shares of common stock issued and outstanding immediately before the effective time were automatically reclassified and combined into 1 share, with fractional shares rounded up to the nearest whole share.¶3¶4
Authorized common shares were reduced from 4,000,000,000 to 50,000,000, while total authorized capital stock was reduced from 4,070,000,000 to 120,000,000.¶5¶6
The common stock is expected to begin split-adjusted trading on Nasdaq at market open on September 11, 2026, under “GOSS” and new CUSIP number 38341P 201.¶7¶1
Stockholders approved the amendment, and the Board set the reverse stock split ratio at 1-for-30, effective at 5:00 p.m. Eastern Time on September 11, 2026.¶2¶1
The reverse stock split converted every 30 shares into one share and reduced issued and outstanding common stock from approximately 270.1 million to approximately 9.1 million.¶3¶4
The reverse stock split adjusted the preferred stock purchase price from $2.25 per one one-thousandth of a share to $67.50 per one one-thousandth of a share, while each share retained one Right.¶5¶6¶7
On September 10, 2026, the Board approved one (1) post-split share for each one thousand five hundred (1,500) pre-split shares and reduced authorized Common Stock from 3,000,000,000 shares to 2,000,000 shares.¶2
On September 11, 2026, the Company filed Articles of Amendment with the Florida Department of State, Division of Corporations, to effect the Reverse Split and Authorized Reduction.¶3
Immediately following the Effective Time, issued and outstanding Common Stock was 846,540 shares against authorized Common Stock of 2,000,000 shares.¶4
On September 10, 2026, NetApp filed the Amended and Restated Charter with Delaware’s Secretary of State, and it became effective upon filing.¶1
Effective September 9, 2026, the Board adopted amended and restated bylaws addressing meeting authority, stockholder-associated persons, share transfers, indemnification, written consents, insurance, and related provisions.¶2¶3¶4¶5¶6¶7¶8¶9¶10¶11
At the Annual Meeting, stockholders elected the listed nominees to serve as directors until the next annual meeting and until their successors are duly elected and qualified.¶12¶13¶14¶15¶16¶17¶18¶19¶20¶21
Stockholders approved executive compensation, Deloitte & Touche LLP’s appointment for the fiscal year ending April 30, 2027, and the Amended and Restated Charter; no vote was taken on the written-consent proposal.¶21¶22¶23¶24¶25¶26¶27
Professional Diversity Network filed a certificate of amendment effecting a one-for-thirty reverse stock split effective at 5:30 p.m. Eastern Time on September 11, 2026.¶2
The reverse stock split consolidates every 30 shares into one share, leaves authorized shares and par value unchanged, and rounds fractional shares up.¶3¶4
The common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the start of trading on September 14, 2026, under a new CUSIP number.¶5¶6
Based on 19,974,323 shares outstanding as of September 9, 2026, approximately 665,811 shares are expected to be outstanding immediately after the split, subject to fractional-share rounding.¶7
On September 10, 2026, GPO Plus, SurgePays and the Acquisition Subsidiary closed the Acquisition, and GPO Plus issued the Preferred Shares to SurgePays.¶1
The Acquisition covered SurgePays’ ClearLine engagement platform, media network, related technology and operating assets, and its GPOX Wireless business and assets for $27,500,000 paid in 25,000,000 Series D Preferred Stock shares.¶2
SurgePays received a right to sell the Preferred Shares or converted common stock to Emerald Shoals for $27,500,000, while Emerald Shoals received a five-year warrant for 15,000,000 common shares.¶3¶4
The Company issued the Preferred Shares and Warrant under Section 4(a)(2) and Rule 506(b), and filed a Certificate of Designation for the Series D Preferred Stock on September 10, 2026.¶5¶6
From August 20, 2026 through September 11, 2026, KULR sold approximately 764 bitcoin through open market transactions to unrelated purchasers.¶1
The Bitcoin Sales represented all of KULR’s remaining BTC holdings, and the Company no longer holds BTC as of the report date.¶1
KULR granted 200,000 time-based restricted stock units to Chief Financial Officer Michael Kimel under the 2025 Equity Incentive Plan.¶2
The restricted stock units vest in eight equal semi-annual installments beginning December 6, 2026, over a total vesting period of four years.¶2
On September 4, 2026, AIB entered agreements to acquire approximately 29.385 acres in Texas with 15 MW of primary electric service on Property A and up to 40 MW on Property B, for approximately $17,225,400.¶1¶2¶3
AIB agreed to acquire approximately 5.00 acres known as Property A for $8,250,000 payable in cash at closing, with an existing Facilities Extension Agreement providing 15 MW of primary electric service.¶4
AIB agreed to acquire 100% of a Delaware limited liability company with rights to approximately 24.385 acres known as Property B for $8,975,400, including a $6,000,000 Deferred Payment.¶5¶6
On September 11, 2026, AIB incurred a $6,000,000 Deferred Payment obligation and caused JPMorgan Chase Bank, N.A. to issue two standby letters of credit with an aggregate face amount of $7,754,640.¶7¶8¶9¶10
